On January 31, 2022 Veracyte, Inc. (Nasdaq: VCYT) reported that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO (Free ASCO Whitepaper) Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif., and virtually, February 17-19, 2022 (Press release, Veracyte, JAN 31, 2022, View Source [SID1234607521]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted abstracts include data from a phase 3 study evaluating the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from their diagnostic biopsy specimen. This is the first late-stage clinical study validating the use of any gene expression classifier as a prognostic biomarker in this setting.
"At this year’s ASCO (Free ASCO Whitepaper) GU Symposium we look forward to sharing data from multiple studies that reinforce the ability of our Decipher genomic classifiers to guide more informed, individualized treatment for patients with urologic cancers," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "The findings offer new insights into how our tests may help physicians stratify risk and guide treatment decisions for their patients with prostate, bladder and kidney cancers."
Below are details of the Veracyte abstracts, which will be presented as posters at the 2022 ASCO (Free ASCO Whitepaper) GU Cancers Symposium being held at Moscone Center. All poster sessions will take place in Moscone West, Level 1.
Date/Time:
February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:
Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126
Presenter:
Daniel E. Spratt, M.D., Case Western Reserve University
Session:
Poster Session A
Date/Time:
February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:
Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829-patient cohort
Presenter:
Adelene Sim, Ph.D., Duke-NUS Medical School
Session:
Poster Session A
Date/Time:
February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:
Transcriptomic Discriminators of Response to Apalutamide in Patients with Prostate Cancer (PC) on Active Surveillance (AS)
Presenter:
Michael Schweizer, M.D., Seattle Cancer Care Alliance
Session:
Poster Session A
Date/Time:
February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:
Impact of AR-V7 and other androgen receptor splice variant expression on outcomes of post-prostatectomy salvage therapy
Presenter:
Keisuke Otani, M.D., Ph.D., Massachusetts General Hospital, Harvard Medical School
Session:
Poster Session A
Date/Time:
February 18, 2022, 12:30-2:00 p.m. PST
Title:
BioMarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy
Presenter:
Shilpa Gupta, M.D., Cleveland Clinic
Session:
Poster Session B
Date/Time:
February 19, 2022, 7:00-8:30 a.m. PST
Title:
Prognostic signatures can further stratify clear cell renal carcinoma clinical risk models in the adjuvant setting
Presenter:
Brian Shuch, M.D., University of California, Los Angeles, Institute of Urologic Oncology
Session:
Poster Session C